| Filed On | Filing |
|---|---|
| 01 Oct 2026 |
Form 4: Jin David, Chief Financial Officer
Received 1,190 shares as a grant or award ($2.16K) |
| 01 Oct 2026 |
8-K: Other Events
As previously disclosed, on July 25, 2024, Fortress Biotech, Inc. (the “Company”), as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and February 22, 2026, the “Oaktree Agreement”)... |
| 01 Sep 2026 | SCHEDULE 13G |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 24 Jun 2026 |
Form 4: Jin David, Chief Financial Officer
Received 400,000 shares as a grant or award |
| 23 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 15 May 2026 | SCHEDULE 13G/A |
| 14 May 2026 | 10-Q |
| 14 May 2026 | 8-K: Results of Operations and Financial Condition |
| 28 Apr 2026 | DEFA14A |
| 28 Apr 2026 |
Proxy statement: annual meeting on June 17, 2026
CEO pay $2.9M, up 109% |
| 01 Apr 2026 |
Form 4: Jin David, Chief Financial Officer
Received 2,967 shares as a grant or award ($6.46K) |
| 31 Mar 2026 | 10-K |
| 31 Mar 2026 | 8-K: Results of Operations and Financial Condition |
| 30 Mar 2026 | 8-K: Other Events |
| 20 Mar 2026 | SCHEDULE 13D/A |
| 20 Mar 2026 |
Form 4: Rosenwald Lindsay A Md, Director
Received 475,424 shares as a grant or award |
| 20 Mar 2026 |
Form 4: Weiss Michael S, Director
Received 475,424 shares as a grant or award |
| 23 Feb 2026 | 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more |
Loading...
